{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:44:42Z","timestamp":1789767882251,"version":"4.0.1"},"reference-count":188,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["cstc2021jcyj-msxmX0298"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0298"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJZD-K202200409"],"award-info":[{"award-number":["KJZD-K202200409"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["D20028"],"award-info":[{"award-number":["D20028"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["W0049"],"award-info":[{"award-number":["W0049"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["202104"],"award-info":[{"award-number":["202104"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.virs.2023.12.005","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T07:12:42Z","timestamp":1702710762000},"page":"9-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9869-659X","authenticated-orcid":false,"given":"Jie-Li","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-9550","authenticated-orcid":false,"given":"Ai-Long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2023.12.005_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.virs.2023.12.005_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virs.2023.12.005_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.virs.2023.12.005_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/v11010030","article-title":"Overview of hcv life cycle with a special focus on current and possible future antiviral targets","volume":"11","author":"Alazard-Dany","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccdna in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.virs.2023.12.005_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib9","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1128\/JVI.00867-09","article-title":"The size of the viral inoculum contributes to the outcome of hepatitis B virus infection","volume":"83","author":"Asabe","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib10","series-title":"Ascentage Pharma. First-in-human Study of apg-1387, Targeting Inhibitor of Apoptosis Proteins, for the Treatment of Patients with Chronic Hepatitis B","year":"2022"},{"key":"10.1016\/j.virs.2023.12.005_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/17460441.2023.2239701","article-title":"The premise of capsid assembly modulators towards eliminating HBV persistence","volume":"18","author":"Bassit","year":"2023","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.virs.2023.12.005_bib12","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following rep 2139-ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.virs.2023.12.005_bib14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/hep4.1767","article-title":"Analysis of HBsAg immunocomplexes and cccDNA activity during and persisting after nap-based therapy","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.virs.2023.12.005_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/gutjnl-2018-317959","article-title":"HBV antiviral immunity: not all CD8 T cells are born equal","volume":"68","author":"Bertoletti","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.virs.2023.12.005_bib16","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191663","article-title":"Challenges of CAR- and TCR-T cell-based therapy for chronic infections","volume":"217","author":"Bertoletti","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2019.02.009","article-title":"Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells","volume":"164","author":"Blanchet","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2017.12.006","article-title":"Research priorities for the discovery of a cure for chronic hepatitis B: report of a workshop","volume":"150","author":"Block","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase ib\/iia study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib21","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific t cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104853","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro","volume":"183","author":"Boulon","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib25","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.3748\/wjg.v21.i15.4644","article-title":"Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine","volume":"21","author":"Bowden","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virs.2023.12.005_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib27","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1002\/iid3.866","article-title":"CRISPR\/Cas9 for hepatitis B virus infection treatment","volume":"11","author":"Cai","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.virs.2023.12.005_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.virs.2023.12.005_bib29","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1128\/JVI.00561-08","article-title":"Properties of subviral particles of hepatitis B virus","volume":"82","author":"Chai","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cld.2012.09.003","article-title":"Hepatitis C viral kinetics: the past, present, and future","volume":"17","author":"Chatterjee","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.virs.2023.12.005_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41580-021-00430-1","article-title":"Cellular origins of DSRNA, their recognition and consequences","volume":"23","author":"Chen","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.virs.2023.12.005_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115485","article-title":"A\u00a0prodrug of the capsid assembly modulator improved druggability and lowing HBsAg and HBeAg for the treatment of chronic hepatitis B","volume":"257","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.virs.2023.12.005_bib34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jvh.13490","article-title":"Clinical effects of NTCP-inhibitor myrcludex B","volume":"28","author":"Cheng","year":"2021","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.virs.2023.12.005_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00535-022-01874-8","article-title":"Serum soluble programmed death-1 levels predict the spontaneous HBsAg seroclearance in chronic hepatitis B","volume":"57","author":"Chu","year":"2022","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.virs.2023.12.005_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coph.2016.08.004","article-title":"Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection","volume":"30","author":"Cole","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.virs.2023.12.005_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41586-022-05545-9","article-title":"R-loop-derived cytoplasmic RNA-DNA hybrids activate an immune response","volume":"613","author":"Crossley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virs.2023.12.005_bib38","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib39","article-title":"Novel insights into double-stranded RNA-mediated immunopathology","author":"de Reuver","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virs.2023.12.005_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03550-22","article-title":"Illuminating the live-cell dynamics of hepatitis B virus covalently closed circular DNA using the CRISPR-Tag system","volume":"14","author":"Ding","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.virs.2023.12.005_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib42","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1073\/pnas.1502400112","article-title":"Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virs.2023.12.005_bib44","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jvh.13608","article-title":"Farnesoid x receptor agonist for the treatment of chronic hepatitis B: a safety study","volume":"28","author":"Erken","year":"2021","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.virs.2023.12.005_bib1","doi-asserted-by":"crossref","first-page":"S1171","DOI":"10.1016\/S0168-8278(23)03317-2","article-title":"Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836","volume":"78","author":"Espiritu","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virs.2023.12.005_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221127848","article-title":"EDP-541 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B","volume":"27","author":"Feld","year":"2022","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virs.2023.12.005_bib47","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1128\/jvi.68.12.8321-8330.1994","article-title":"Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks","volume":"68","author":"Fourel","year":"1994","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib48","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200298","article-title":"Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection","volume":"217","author":"Fumagalli","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib49","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.virs.2023.12.005_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/jhep.2002.31867","article-title":"Clinical evaluation (phase i) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties","volume":"35","author":"Galun","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib51","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2023.07.026","article-title":"First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection","volume":"79","author":"Gane","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib53","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1128\/JVI.02721-06","article-title":"Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein","volume":"81","author":"Gao","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/jvh.13425","article-title":"What drives the dynamics of HBV RNA during treatment?","volume":"28","author":"Goncalves","year":"2021","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.virs.2023.12.005_bib55","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12072-011-9261-3","article-title":"HBV life cycle and novel drug targets","volume":"5","author":"Grimm","year":"2011","journal-title":"Hepatol Int"},{"key":"10.1016\/j.virs.2023.12.005_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.virs.2023.12.005_bib57","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrc2889","article-title":"IAPs: from caspase inhibitors to modulators of nf-kappab, inflammation and cancer","volume":"10","author":"Gyrd-Hansen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.virs.2023.12.005_bib59","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cpdd.670","article-title":"A\u00a0randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects","volume":"8","author":"Han","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.virs.2023.12.005_bib60","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpdd.1154","volume":"11","author":"Han","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.virs.2023.12.005_bib61","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cels.2022.05.001","article-title":"Diploid hepatocytes drive physiological liver renewal in adult humans","volume":"13","author":"Heinke","year":"2022","journal-title":"Cell Syst"},{"key":"10.1016\/j.virs.2023.12.005_bib62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/nar\/gkj440","article-title":"The hepatitis B virus pre contains a splicing regulatory element","volume":"34","author":"Heise","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virs.2023.12.005_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.virs.2023.12.005_bib190","article-title":"ALG-000184, an Orally Administered Capsid Assembly Modulator (CAM) Reduces HBsAg in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)","author":"Hou","year":"2023","journal-title":"The APASL annual meeting"},{"key":"10.1016\/j.virs.2023.12.005_bib64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41435-019-0078-8","article-title":"Inhibitor of apoptosis proteins in human health and disease","volume":"20","author":"Hrdinka","year":"2019","journal-title":"Gene Immun."},{"key":"10.1016\/j.virs.2023.12.005_bib65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/microorganisms11030600","article-title":"Dynamics of hepatitis B virus covalently closed circular DNA: a mini-review","volume":"11","author":"Hu","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.virs.2023.12.005_bib66","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virs.2023.12.005_bib68","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1073\/pnas.1808319115","article-title":"N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle","volume":"115","author":"Imam","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virs.2023.12.005_bib69","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","article-title":"Randomised phase 2 study (jade) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","volume":"72","author":"Janssen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.virs.2023.12.005_bib70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12916-023-02814-w","article-title":"Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial","volume":"21","author":"Jia","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.virs.2023.12.005_bib72","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virs.2023.12.005_bib73","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-017-9829-7","article-title":"Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread","volume":"11","author":"Karayiannis","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.virs.2023.12.005_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198191","article-title":"Development of an in vivo delivery system for CRISPR\/Cas9-mediated targeting of hepatitis B virus cccDNA","volume":"290","author":"Kayesh","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.virs.2023.12.005_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2019.109316","article-title":"Rethinking the pragmatic systems biology and systems-theoretical biology divide: toward a complexity-inspired epistemology of systems biomedicine","volume":"131","author":"Kesic","year":"2019","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.virs.2023.12.005_bib76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3350\/cmh.2013.19.1.17","article-title":"Hepatitis C virus: virology and life cycle","volume":"19","author":"Kim","year":"2013","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib77","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.3748\/wjg.v22.i31.7017","article-title":"Roles of hepatocyte nuclear factors in hepatitis B virus infection","volume":"22","author":"Kim","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virs.2023.12.005_bib78","article-title":"In vivo genome editing with a small Cas9 orthologue derived from campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virs.2023.12.005_bib79","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.3390\/molecules26247420","article-title":"Current progress in the development of hepatitis B virus capsid assembly modulators: chemical structure, mode-of-action and efficacy","volume":"26","author":"Kim","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.virs.2023.12.005_bib80","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.13659","article-title":"Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients","volume":"44","author":"Lampertico","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.virs.2023.12.005_bib82","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010213","article-title":"Hepatitis B virus cure: targets and future therapies","volume":"22","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virs.2023.12.005_bib84","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib85","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.virs.2022.03.001","article-title":"Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBsAg positive chronic hepatitis B patients","volume":"37","author":"Li","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virs.2023.12.005_bib86","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/vim.2023.0077","article-title":"Toll-like receptors 7\/8: a paradigm for the manipulation of immunologic reactions for immunotherapy","volume":"36","author":"Li","year":"2023","journal-title":"Viral Immunol."},{"key":"10.1016\/j.virs.2023.12.005_bib87","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virs.2023.12.005_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coviro.2021.04.009","article-title":"Hepatitis B virus-host interactions and novel targets for viral cure","volume":"49","author":"Ligat","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.virs.2023.12.005_bib89","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccdna minichromosomes","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virs.2023.12.005_bib91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12250-018-0062-x","article-title":"Targeting ciaps, a new option for functional cure of chronic hepatitis B infection?","volume":"33","author":"Liu","year":"2018","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virs.2023.12.005_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00574-21","article-title":"Host poly(a) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B RNA","volume":"95","author":"Liu","year":"2021","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/v13050777","article-title":"Animal models of hepatitis B virus infection-success, challenges, and future directions","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib94","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase ii study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib95","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib96","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib97","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.virs.2023.12.005_bib98","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/archinte.1961.03620030023003","article-title":"\"Lifespan\" of liver cells. Autoradio-graphic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats","volume":"107","author":"Macdonald","year":"1961","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib99","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B","volume":"63","author":"Mackman","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.virs.2023.12.005_bib100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1034\/j.1600-0676.2002.01702.x","article-title":"Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver","volume":"22","author":"Magami","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.virs.2023.12.005_bib101","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/v13061169","article-title":"Novel antivirals in clinical development for chronic hepatitis B infection","volume":"13","author":"Mak","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib102","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molmed.2022.06.002","article-title":"New strategies for the treatment of chronic hepatitis B","volume":"28","author":"Mak","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib103","series-title":"Low HBsAg Levels Maintained Following Cessation of the GalNAc-siRNA, AB-729, in Chronic Hepatitis B Subjects on Nucleos(t)ide Analogue Therapy","author":"Man-Fung","year":"2021"},{"key":"10.1016\/j.virs.2023.12.005_bib104","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02888-21","article-title":"CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants","volume":"13","author":"Martinez","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.virs.2023.12.005_bib106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-27-48","article-title":"Role of Smac\/DIABLO in cancer progression","volume":"27","author":"Martinez-Ruiz","year":"2008","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.virs.2023.12.005_bib107","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1128\/JVI.01587-08","article-title":"The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir","volume":"83","author":"Mason","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007467","article-title":"Impact of a patient-derived hepatitis C viral RNA genome with a mutated microrna binding site","volume":"15","author":"Mata","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virs.2023.12.005_bib109","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.virs.2023.12.005_bib110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1172\/JCI116950","article-title":"Hepatitis B virus persistence after recovery from acute viral hepatitis","volume":"93","author":"Michalak","year":"1994","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.virs.2023.12.005_bib111","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1126\/science.3491425","article-title":"The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen","volume":"234","author":"Milich","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.virs.2023.12.005_bib112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/nat.2017.0709","article-title":"Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver","volume":"28","author":"Miller","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.virs.2023.12.005_bib113","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3389\/fmicb.2018.00662","article-title":"An overview of hepatitis B virus surface antigen secretion inhibitors","volume":"9","author":"Mohebbi","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virs.2023.12.005_bib114","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/v14040657","article-title":"HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure","volume":"14","author":"Moini","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib115","doi-asserted-by":"crossref","first-page":"es3","DOI":"10.1187\/cbe.21-05-0118","article-title":"Using systems and systems thinking to unify biology education","volume":"21","author":"Momsen","year":"2022","journal-title":"CBE-Life Sci. Educ."},{"key":"10.1016\/j.virs.2023.12.005_bib116","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1096\/fj.201801181R","article-title":"Farnesoid x receptor-alpha is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo","volume":"33","author":"Mouzannar","year":"2019","journal-title":"Faseb. J."},{"key":"10.1016\/j.virs.2023.12.005_bib117","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-med-080119-103356","article-title":"New therapeutics for hepatitis B: the road to cure","volume":"72","author":"Naggie","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09776-z","article-title":"The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?","volume":"7","author":"Nguyen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virs.2023.12.005_bib119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cbpa.2019.02.009","article-title":"Recent advances in the development of HBV capsid assembly modulators","volume":"50","author":"Nijampatnam","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.virs.2023.12.005_bib120","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: an expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.virs.2023.12.005_bib121","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virs.2023.12.005_bib122","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virs.2023.12.005_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1128807","article-title":"The progress of molecules and strategies for the treatment of HBV infection","volume":"13","author":"Pan","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.virs.2023.12.005_bib124","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B virus--specific and global T-cell dysfunction in chronic hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib125","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.virs.2023.12.005_bib126","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2020.11.056","article-title":"Animal models for hepatitis B: does the supply meet the demand?","volume":"160","author":"Ploss","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib127","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.virs.2023.12.005_bib128","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/v13030368","article-title":"HBV-integration studies in the clinic: role in the natural history of infection","volume":"13","author":"Pollicino","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib129","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virs.2023.12.005_bib131","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1096\/fj.201500134","article-title":"Reciprocal regulation of farnesoid x receptor alpha activity and hepatitis B virus replication in differentiated heparg cells and primary human hepatocytes","volume":"30","author":"Radreau","year":"2016","journal-title":"Faseb. J."},{"key":"10.1016\/j.virs.2023.12.005_bib132","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.virs.2023.12.005_bib133","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat. Med."},{"issue":"Suppl 1","key":"10.1016\/j.virs.2023.12.005_bib134","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: new therapeutic strategies against an old foe","volume":"41","author":"Roca Suarez","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2023.12.005_bib135","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2022-327202","article-title":"Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro","volume":"72","author":"Rossi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.virs.2023.12.005_bib136","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2017.10.022","article-title":"Activity of nucleic acid polymers in rodent models of HBV infection","volume":"149","author":"Schoneweis","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib137","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib138","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.chom.2014.07.006","article-title":"Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2","volume":"16","author":"Sedano","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virs.2023.12.005_bib139","article-title":"Assembly and release of hepatitis B virus","volume":"5","author":"Selzer","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virs.2023.12.005_bib141","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008730","article-title":"Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation","volume":"5","author":"Silke","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.virs.2023.12.005_bib142","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-8278(01)00264-1","article-title":"The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication","volume":"36","author":"Sobao","year":"2002","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib143","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.virs.2023.12.005_bib144","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1440-1746.2011.06766.x","article-title":"Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir","volume":"26","author":"Takkenberg","year":"2011","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104748","article-title":"Adoptive T-cell therapy for HBV-associated HCC and HBV infection","volume":"176","author":"Tan","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib146","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib147","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib148","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy","volume":"29","author":"Tsiang","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib149","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3748\/wjg.v27.i21.2727","article-title":"Toward a new era of hepatitis B virus therapeutics: the pursuit of a functional cure","volume":"27","author":"Tsounis","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virs.2023.12.005_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib151","article-title":"Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells","volume":"4","author":"Tu","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.virs.2023.12.005_bib152","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/v12020160","article-title":"Host transcription factors in hepatitis B virus RNA synthesis","volume":"12","author":"Turton","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib153","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3390\/v14092052","article-title":"Oligonucleotide-based therapies for chronic HBV infection: a primer on biochemistry, mechanisms and antiviral effects","volume":"14","author":"Vaillant","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib154","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1600-0676.2001.021003207.x","article-title":"Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients","volume":"21","author":"van Nunen","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.virs.2023.12.005_bib155","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients","volume":"133","author":"Volz","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib156","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor myrcludex-b efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib191","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(22)00538-4","article-title":"ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs","volume":"77","author":"Wang","year":"2022","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib157","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7150\/ijms.71737","article-title":"Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients","volume":"19","author":"Wang","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.virs.2023.12.005_bib158","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib159","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/jhep.2000.19324","article-title":"Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms","volume":"32","author":"Webster","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2023.12.005_bib161","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hep.32109","article-title":"Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: a randomized clinical trial","volume":"75","author":"Wei","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib162","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib163","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1172\/JCI120228","article-title":"T\u00a0cell receptor grafting allows virological control of hepatitis B virus infection","volume":"129","author":"Wisskirchen","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.virs.2023.12.005_bib164","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-8278(02)00115-0","article-title":"Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B","volume":"37","author":"Wolters","year":"2002","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0676.2002.01579.x","article-title":"Viral dynamics in chronic hepatitis B patients during lamivudine therapy","volume":"22","author":"Wolters","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.virs.2023.12.005_bib166","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virs.2023.12.005_bib167","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virs.2023.12.005_bib168","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.SCI","volume":"9","author":"Wooddell","year":"2017","journal-title":"Transl. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.virs.2023.12.005_bib171","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/v14010004","article-title":"Recent progress and future prospective in HBV Cure by CRISPR\/Cas","volume":"14","author":"Yang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2023.12.005_bib172","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2023.12.005_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105618","article-title":"Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models","volume":"215","author":"Yi","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2023.12.005_bib174","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/gut.2005.065136","article-title":"Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications","volume":"54","author":"Yuen","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.virs.2023.12.005_bib175","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.virs.2023.12.005_bib176","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2023.12.005_bib177","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib178","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.virs.2023.12.005_bib179","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib180","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase iia, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib181","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2023.12.005_bib182","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(22)00727-7","article-title":"TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial","volume":"23","author":"Yuen","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2023.12.005_bib183","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.virs.2023.12.005_bib130","doi-asserted-by":"crossref","first-page":"S880","DOI":"10.1016\/S0168-8278(20)32200-5","article-title":"ALG-000184, a prodrug of capsid assembly modulator ALG-001075 demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B.","volume":"73","author":"Zhang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2023.12.005_bib184","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2023.12.005_bib185","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jvh.12261","article-title":"Decline in intrahepatic cccdna and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss","volume":"21","author":"Zheng","year":"2014","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.virs.2023.12.005_bib186","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.virs.2023.12.005_bib187","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2023.12.005_bib188","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine tg1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virs.2023.12.005_bib189","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X23001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X23001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:39:53Z","timestamp":1778834393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X23001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":188,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1995820X23001578"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2023.12.005","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}